FDA Accepts GSK's NDA for Linerixibat in Rare Disease-Related Itch

The FDA has accepted GSK's NDA for linerixibat, a targeted inhibitor of the ileal bile acid transporter (IBAT), for treating cholestatic pruritus in patients with primary biliary cholangitis (PBC); a regulatory decision is expected by March 24, 2026. The NDA is based on Phase III GLISTEN study data showing rapid and significant improvement in itch versus placebo, potentially making it the first global therapy for PBC-related itch. Gilead Sciences' Livdelzi (seladelpar) was recently approved for PBC, and Mirum Pharmaceuticals is also developing a treatment, volixibat, for the same condition.

Analysis

The U.S. Food and Drug Administration (FDA) has accepted GSK's New Drug Application (NDA) for linerixibat, an investigational inhibitor of the ileal bile acid transporter (IBAT), for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC). A regulatory decision is anticipated by March 24, 2026. This NDA submission is supported by data from the Phase III GLISTEN study, announced in November 2024, which demonstrated that linerixibat led to rapid, significant, and sustained improvements in cholestatic pruritus and itch-related sleep interference compared to placebo. If approved, linerixibat has the potential to be the first global therapy specifically indicated for PBC-related itch, addressing a significant unmet medical need. GSK's stock has demonstrated strong performance, rallying 23.2% year-to-date, outperforming the industry's 3.8% decline. In the competitive PBC landscape, Gilead Sciences received FDA accelerated approval in August 2024 for Livdelzi (seladelpar), a drug added to its portfolio through the $4.3 billion acquisition of CymaBay Therapeutics in March 2024. Mirum Pharmaceuticals is also developing volixibat, another oral IBAT inhibitor, for PBC, with its Phase IIb VANTAGE study expected to complete enrollment in 2026. Separately, Immunocore Holdings is highlighted as a top-ranked biotech stock, with its loss per share estimates for 2025 narrowing significantly from $1.57 to $0.86 and for 2026 from $1.80 to $1.34 in the past 60 days, coupled with a 31.1% year-to-date share price increase and an average earnings surprise of 76.18% over the trailing four quarters.

Key Decisions for Investors

• Investors should recognize the FDA's acceptance of GSK's linerixibat NDA as a positive development, while noting the PDUFA date of March 24, 2026, implies a long-term horizon for potential commercialization and revenue impact.
• It is advisable to closely monitor competitive developments in the PBC market, specifically the market penetration and performance of Gilead's recently approved Livdelzi and the ongoing clinical trial progress of Mirum Pharmaceuticals' volixibat, as these factors will significantly shape linerixibat's market opportunity if approved.
• Given GSK's substantial year-to-date share price appreciation of 23.2%, investors should weigh this against the extended timeline to linerixibat's potential approval and market entry when considering adjustments to their GSK positions.